Trial Profile
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Pituitary ACTH hypersecretion
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 18 May 2022 Results from LINC-3, CSOM230G2304 and other study evaluating the relative time to complete response (CR) of osilodrostat compared with pasireotide subcutaneous (SC) and long-acting release (LAR) for patients with CD presented at the 27th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 10 Jan 2022 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI111695).
- 08 May 2020 Results assessing whether, Long-acting pasireotide improves clinical signs and quality of life in Cushing's disease, published in the Journal of Endocrinological Investigation